Published online Oct 14, 2016. doi: 10.3748/wjg.v22.i38.8519
Peer-review started: June 4, 2016
First decision: July 12, 2016
Revised: July 27, 2016
Accepted: August 19, 2016
Article in press: August 19, 2016
Published online: October 14, 2016
Processing time: 130 Days and 1.6 Hours
To investigate the role of embryonic liver fordin (ELF) in liver fibrosis by regulating hepatic stellate cells (HSCs) glucose glycolysis.
The expression of ELF and the glucose glycolysis-related proteins were evaluated in activated HSCs. siRNA was used to silence ELF expression in activated HSCs in vitro and the subsequent changes in PI3K/Akt signaling and glucose glycolysis-related proteins were observed.
The expression of ELF increased remarkably in HSCs of the fibrosis mouse model and HSCs that were cultured for 3 wk in vitro. Glucose glycolysis-related proteins showed an obvious increase in the activated HSCs, such as phosphofructokinase, platelet and glucose transporter 1. ELF-siRNA, which perfectly silenced the expression of ELF in activated HSCs, led to the induction of glucose glycolysis-related proteins and extracellular matrix (ECM) components. Moreover, pAkt, which is an important downstream factor in PI3K/Akt signaling, showed a significant change in response to the ELF silencing. The expression of glucose glycolysis-related proteins and ECM components decreased remarkably when the PI3K/Akt signaling was blocked by Ly294002 in the activated HSCs.
ELF is involved in HSC glucose glycolysis by regulating PI3K/Akt signaling.
Core tip: The metabolism of activated hepatic stellate cells (HSCs) was reprogrammed. Silence of embryonic liver fordin (ELF) led to the inhibition of PI3K/Akt signaling and decrease of glycolysis in activated HSCs. Glucose glycolysis of activated HSCs was regulated by ELF through PI3K/Akt signaling The present study indicated that metabolism of HSCs may be a novel target for the diagnosis and treatment of liver cirrhosis in clinical practice.